Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Loyola study finds radiation as a risk factor for young people with meningioma

Loyola study finds radiation as a risk factor for young people with meningioma

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Melbourne researchers reveal key steps involved in programmed cell death

Melbourne researchers reveal key steps involved in programmed cell death

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

Stem cell technologies market expected to show annual increase of 16.2% over 2010-2020

BloodCenter of Wisconsin announces availability of cancer mutation HemeOnc Panel

BloodCenter of Wisconsin announces availability of cancer mutation HemeOnc Panel

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

New standard of care for pediatric AML patients who receive umbilical cord transplants

New standard of care for pediatric AML patients who receive umbilical cord transplants

Study: Obese youths with ALL have worse outcomes than lean counterparts

Study: Obese youths with ALL have worse outcomes than lean counterparts

Bortezomib drug effective against chronic GVHD

Bortezomib drug effective against chronic GVHD

CTI BioPharma acquires worldwide rights to tosedostat

CTI BioPharma acquires worldwide rights to tosedostat

Tiny nano-sized particles may play major role in detecting, tracking breast cancer

Tiny nano-sized particles may play major role in detecting, tracking breast cancer

UC San Diego Sanford Stem Cell Clinical Center named new 'alpha clinic'

UC San Diego Sanford Stem Cell Clinical Center named new 'alpha clinic'

High risk for congenital heart defects in Down syndrome provides tool to identify changes in genes

High risk for congenital heart defects in Down syndrome provides tool to identify changes in genes

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Genetic changes in blood cells of older people linked to lymphoma, leukemia

Genetic changes in blood cells of older people linked to lymphoma, leukemia

Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

VAL-083 drug compound shows promise against non-small cell lung cancer

VAL-083 drug compound shows promise against non-small cell lung cancer

CleveXel Pharma receives license for two new oncology patents

CleveXel Pharma receives license for two new oncology patents

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.